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Introduction
Cancer diagnosis in primary care is an important challenge for general practitioners (GPs) due to the relatively low frequency of any single type of cancer and the heterogeneous signs and symptoms that can be present. In addition to analytical reasoning, GPs may become aware of gut feelings (GFs) as they suspect that a patient may have cancer or another serious disease. We aim to investigate the prevalence and predictive value of GFs for the diagnosis of cancer and serious diseases.
Methods and analysis
Prospective observational study of diagnostic validity. Participation will be offered to GPs from Majorca and Zaragoza. They will recruit all patients with a new reason for encounter during one or two workdays. GPs will complete the Gut Feelings Questionnaire (GFQ). Variables regarding patient, GP and consultation will be collected. Two and six months after the first visit, incident diagnoses of cancer or other serious diseases, diagnostic tests performed, referrals and new visits will be recorded.
Analysis will include descriptive analysis of the variables and prevalence of GFs, and the sensitivity, specificity, predictive values, and likelihood ratios of the GFs (sense of alarm and sense of reassurance) for diagnosing cancer and other serious diseases, as measured with the GFQ.
Ethics and dissemination
The study has obtained approval from the Majorcan Primary Care Research Committee and from the Balearic Islands Ethical Committee, with reference number IB 3210/16 PI.
The results may help GPs to make more accurate decisions about which patients need further examinations to rule out or confirm a diagnosis of cancer or a serious disease, and which ones do not. The results will be published as part of the PhD project of the first author, in open access journals, and presented at medical conferences 
Strengths and limitations of this study
-This is the first study to use an objective tool (the Gut Feeling Questionnaire) to assess the prevalence and the diagnostic value of GFs for the diagnosis of cancer and other serious diseases. -We will analyse variables that can affect the prevalence and diagnostic value of GFs. -The results of this study may help to estimate the extent to which GPs' gut feelings can contribute to the diagnosis of cancer and serious diseases. Establishing a diagnosis of cancer in primary care presents many difficulties. A cancer diagnosis is not a rare event, since a general practitioner (GP) with 2000 registered patients will see 6-8 new cases per year. But a GP will on average diagnose a case of each of the most common cancers (colorectal, prostate, breast, and lung) only once a year, and less frequent cancers might be seen only once or twice during a GP's career. [1] In addition, signs and symptoms of cancer are different for each cancer type, and these signs and symptoms are very common, and mostly relate to mild diseases. Even those considered to be alarming symptoms have low positive predictive values for cancer diagnosis; only eight signs and symptoms (rectal bleeding, iron deficiency anaemia, haematuria, rectal examination showing malignancy, haemoptysis, dysphagia, breast lump and postmenopausal bleeding) have a positive predictive value above 5%. [2] . Since half of cancer patients do not have alarming symptoms [3] , there is a growing interest in finding new elements in the diagnostic process that would lead to an earlier diagnosis in primary care with better survival results.
Uncertainty is an intrinsic component of any clinical encounter in general practice. To cope with it, GPs not only use analytical processes, but sometimes rely on what they call a gut feeling (GF) or an intuition. [4] Gut feelings have been described as "a useful warning light that goes on suddenly to announce that there is something unusual". [5] It is in the grey area of common symptoms and vague signs, where uncertainty dominates, that GPs might gain the greatest benefit of becoming aware of GFs. When they do so, they have to ask more specific questions, to adopt an even more attentive attitude, and observe more accurately to find the trigger that gave them the sense of alarm. The role of gut feelings in the GP's diagnostic process has been studied in countries such as the Netherlands, Belgium, France and Spain. [6] [7] [8] [9] These studies show two types of GF. The first one is a sense of alarm, described as the feeling that something does not fit for a particular patient, making the GP worried about a possible serious outcome. The second type of GF consists of a sense of reassurance, in which the doctor is sure about the future evolution and management of the patient, even if he/she does not yet know the precise diagnosis. The majority of studies on GFs carried out so far have used qualitative methodology. As a result of the findings, Dutch and Belgian researchers have created and validated the Gut Feelings Questionnaire (GFQ) to objectify their occurrence in clinical encounters. [10] The Dutch GFQ has been translated and linguistically validated into English, French, German, Polish, Spanish, and Catalan. [11, 12] 
Limitations of existing literature
The sense of alarm arises especially when diffuse symptoms are suspected to hide a neoplasm [6, 7, 9] . The role of GFs in the diagnosis of cancer has been little studied so far.
In an English study, 55 GPs were interviewed about the role of GFs in the screening and early diagnosis of cancer.
[13] They referred to GFs as a tool, developed through experience, useful to identify patients who need more complementary tests, either to confirm or rule out the possible presence of cancer. Norwegian GPs were asked how they came to think of cancer in a clinical encounter. [4] They mentioned intuition and GFs as one of the ways in which that idea arises. They described GFs as resulting from their medical knowledge, accumulated expertise and knowledge about the patient and their community. There have also been two Danish studies using a quantitative approach to determine the accuracy with which GPs diagnose cancer. In one of them, 4518 consultations were studied. [14] After each consultation, the GP answered the question whether he had any suspicion of cancer or serious illness. The suspicion of cancer had a positive predictive value (PPV) of 3.1% and a negative predictive value (NPV) of 99.5% six months after the consultation. The other study examined the reasons for referral for further diagnostic workup in a cancer pathway among 1218 patients with nonspecific symptoms and signs. [15] GPs' gut feelings were the second most common reason for referral (22.5% of cases) and a cancer diagnosis was established in 24% of these cases. Dutch GPs reported GFs relating to the diagnosis of cancer in 20 out of 10,000 registered patients a year. These GFs were more likely to arise for patients with weight loss and patients who visited their GP infrequently. The predictive value of GFs for cancer diagnosis was 35%, a value that increased with patients' or GPs' age. [16] We aim to study the diagnostic value of the GFQ for the diagnosis of cancer. Some studies have suggested that this diagnostic validity may be comparable to that of the recognized cancer alarm symptoms.[2,17] If these results were confirmed, a GP's sense of alarm about possible cancer could be regarded as another alarm symptom or "red flag". In the same vein, GFs could be incorporated into the clinical training about the diagnostic process for medical students and residents.
Objectives
The aim of the study is to assess the diagnostic value of GPs' sense of alarm and sense of reassurance (in terms of sensitivity, specificity, predictive values and likelihood ratios) for cancer and other serious diseases in clinical consultations. The relationships, if any, between the diagnostic value of GFs and patient characteristics (sociodemographic and clinical) and with GP characteristics (gender, experience, personality, type of practice, and knowledge about the patient) will also be assessed. A secondary objective is to establish the prevalence of GFs in GPs' consultations, as well as the possible relationship between the prevalence of GFs and patient and GP characteristics. We aim to estimate the relationship between GFs (sense of alarm and sense of reassurance) with requests for tests and investigations as well as referrals to hospital specialists.
Methods and analysis
This is a prospective observational study using the Spanish and Catalan versions of the GFQ.
Participants
GPs from the regions of Majorca and Zaragoza (Spain) will be invited to participate. All patients seen by a GP during a working day with a new reason for consultation will be included. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 A member of the researcher team will introduce the study in Majorca and Zaragoza health centres. We will include similar proportions of teaching and non-teaching centres as well as rural and urban centres. Those doctors who agree to participate will sign an informed consent form and receive a unique identification code. They will receive instructions about how to record the variables used in the study and how to complete the GFQ.
GP inclusion:

Patient inclusion:
All patients consulting their GP for at least one new reason during one whole working day will be included. Scheduled visits, non-scheduled visits, home visits and telephone contacts will be included. Patients will receive an information sheet explaining the objectives and procedures of the study. If they agree to participate, they will sign an informed consent form. 
Sample size:
Our sample size estimation was based on the Hjertholm study, [14] which found the prevalence and positive predictive value of cancer suspicion in GPs' consultations to be 6% and 5.4%, respectively. Using an intraclass correlation coefficient correction and a proportion of losses of 10% we will need a sample of 2,966 patients.
Data collection:
During the consultations, GPs will check inclusion and exclusion criteria and obtain informed consent. They will record demographic and clinical data and complete the GFQ. The actual study will start after a pilot to assess the feasibility.
Follow-up: Two data managers will record the follow-up variables and outcomes. The presence of new diagnoses of cancer or serious disease will be recorded 2 and 6 months after the consultations. The incidence of cancer and serious disease will be assessed by reviewing the hospital and primary care electronic clinical records. [14] all new diagnoses will be assessed by two researchers to decide if they are serious or not. Disagreements will be discussed and presented to a third researcher until agreement is reached. -All diagnostic tests performed during the follow-up period. Referrals to specialized care and emergency departments. -Numbers of consultations for any reason during the follow-up period. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [10] . The validated Spanish and Catalan versions will be used. [12] . The GFQ consists of 11 items. Item 1 (repeated at the end as item 11) assesses whether the patient's case elicited a GF. Items 2-6 are rated using a 5-point Likert scale ranging from completely disagree to completely agree. Item 2 concern the sense of reassurance and items 3-6 concern the sense of alarm. A sense of alarm is considered to be present when the answer to item 1 or 11 indicates a sense of alarm or when the answer chosen at item 1 or 11 is "not applicable" and at least one of the scores of items 3-6 is higher than 3/5. A sense of reassurance is considered to be present when the answer to items 1 or 11 indicates a sense of reassurance or when the answer chosen at items 1 or 11 is "not applicable" and the score for item 2 is higher than 3/5. No type of GF is considered to be present when the answer chosen at item 1 or 11 is "not applicable", none of the scores for items 3-6 is higher than 3/5 and the score for item 2 is lower than 4/5.
Measurements
Outcomes (Follow-up variables):
Independent variables:
Statistical analysis
Objective 1 Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios will be calculated for both sense of alarm and sense of reassurance. For the purpose of this calculation, we will assume that positive values for the sense of reassurance aim to identify the healthy patients, whereas positive values for the sense of alarm aim to identify ill patients. The outcome will be the diagnosis of cancer or a serious disease during the follow-up period. Confidence intervals will be obtained for each parameter. Bivariate analysis will be used to explore the relationship between the sense of alarm and sense of security and the patient and GP characteristics.
Objective 2. We will perform a descriptive analysis of all selected variables in order to describe sample characteristics and the prevalence of gut feelings.
Objective 3. A bivariate analysis with the chi-squared test will be carried out, in which each of the main variables (presence of sense of reassurance or sense of alarm) will be compared with the patient and GP characteristics. A multivariate logistic regression analysis will be used to assess the independent relationships between the variables and the presence of GFs. Interactions will be tested. SPSS software will be used for the analysis.
Schedule
All the documents (information sheet, informed consent forms, data collection sheets) have already been designed. Data will be collected during May, June and July 2019. Follow-up variables will be collected during August, September and October 2019 (2months' follow-up) and December 2019, January and February 2020 (6-months' followup).
Ethics
GPs will explain to their patients the study objectives and procedures and request their agreement to collect information from their clinical records. If they agree to participate, patients will sign an informed consent form. The study will be carried out in accordance with the principles of the Helsinki statement and good clinical practice standards. The study has obtained approval of the Majorcan Primary Care Research Committee and the Balearic Islands Ethical Committee, with reference number IB 3210/16 PI.
Limitations
The sample size necessary to perform a diagnostic validity study of these characteristics is very large. The design we chose aims to have minimal impact on the consultations of the collaborating doctors, in order to facilitate their participation and the inclusion of patients. It is also a very adaptable design, since the number of recruitment days can be increased until the desired sample size is reached, although efforts will be made to include a large number of professionals to ensure sufficient practice variation. Selection bias is controlled by the consecutive inclusion of patients and by the instructions previously given to the collaborating physicians. To minimize the number of missing diagnostic records, the patient files of both primary and hospital care will be thoroughly reviewed. In case of doubt, the seriousness of the diagnoses will be confirmed by peer review. 
Dissemination
The results of this study may help to estimate the extent to which GPs' gut feelings can contribute to the diagnosis of cancer and serious diseases. It will help GPs make more accurate decisions about which patients need further investigations and which ones do not.
This study is part of the corresponding author's PhD project, and its results will be published as part of the thesis, in open access journals, and presented at medical conferences.
This study is part of the corresponding author's PhD project. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Introduction
Methods and analysis
Ethics and dissemination
The results may help GPs to make more accurate decisions about which patients need further examinations to rule out or confirm a diagnosis of cancer or a serious disease, and which ones do not. The results will be published as part of the PhD project of the first author, in open access journals, and presented at medical conferences 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Strengths and limitations of this study
-This is the first study to use an objective tool (the Gut Feeling Questionnaire) to assess the prevalence and the diagnostic value of GFs for the diagnosis of cancer and other serious diseases. -We will analyse variables that can affect the prevalence and diagnostic value of GFs. -The results of this study may help to estimate the extent to which GPs' gut feelings can contribute to the diagnosis of cancer and serious diseases. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Establishing a diagnosis of cancer in primary care presents many difficulties. A cancer diagnosis is not a rare event, since a general practitioner (GP) with 2000 registered patients will see 6-8 new cases per year. But a GP will on average diagnose a case of each of the most common cancers (colorectal, prostate, breast, and lung) only once a year, and less frequent cancers might be seen only once or twice during a GP's career.
[1] In addition, signs and symptoms of cancer are different for each cancer type, and these signs and symptoms are also very common in other, mostly mild, diseases. Even those considered to be alarming symptoms have low positive predictive values for cancer diagnosis; only eight signs and symptoms (rectal bleeding, iron deficiency anaemia, haematuria, rectal examination showing malignancy, haemoptysis, dysphagia, breast lump and postmenopausal bleeding) have a positive predictive value above 5%.
[2]. Since half of cancer patients do not have alarming symptoms [3] , there is a growing interest in finding new elements in the diagnostic process that would lead to an earlier diagnosis in primary care with better survival results.
Limitations of existing literature
[13] They referred to GFs as a tool, developed through experience, useful to identify patients who need more complementary tests, either to confirm or rule out the possible presence of cancer. Norwegian GPs were asked how they came to think of cancer in a clinical encounter. [4] They mentioned intuition and GFs as one of the ways in which that idea arises. They described GFs as resulting from their medical knowledge, accumulated expertise and knowledge about the patient and their community. There have also been two Danish studies using a quantitative approach to determine the accuracy with which GPs diagnose cancer. In one of them, 4518 consultations were studied. [14] After each consultation, the GP answered the question whether he had any suspicion of cancer or serious illness. The suspicion of cancer had a positive predictive value (PPV) of 3.1% and a negative predictive value (NPV) of 99.5% six months after the consultation. The other study examined the reasons for referral for further diagnostic workup in a cancer pathway among 1218 patients with nonspecific symptoms and signs. [15] GPs' gut feelings were the second most common reason for referral (22.5% of cases) and a cancer diagnosis was established in 24% of these cases. Dutch GPs reported GFs relating to the diagnosis of cancer in 20 out of 10,000 registered patients a year. These GFs were more likely to arise for patients with weight loss and patients who visited their GP infrequently. The predictive value of GFs for cancer diagnosis was 35%, a value that increased with patients' or GPs' age. [16] We aim to study the diagnostic value of the GFQ for the diagnosis of cancer. Some studies have suggested that this diagnostic validity may be comparable to that of the recognized cancer alarm symptoms.[2,17] If these results were confirmed, a GP's sense of alarm about possible cancer could be regarded as another alarm symptom or "red flag". GFs could be incorporated into the clinical training about the diagnostic process for medical students and residents. We will also address the sense of reassurance. We think, as GPs in previous qualitative literature, that it could be a very useful tool for doctors and patients for avoiding unnecessary tests that could result in overmedicalization and overdiagnosis.
Objectives
Methods and analysis
This is a prospective observational study using the Spanish and Catalan versions of the GFQ. GPs from the regions of Majorca and Zaragoza sector 1 (Spain) will be invited to participate. In Spain every GP has his/her own patient lists. Patients are mainly attended in their health centre by their GP, except during holidays, sick-leave or in out of hours visits.
Participants
GP inclusion:
A member of the researcher team will introduce the study in Majorca and Zaragoza health centres, inviting doctors to participate in the study. We will include similar proportions of teaching and non-teaching centres as well as rural and urban centres. Those doctors who agree to participate will sign an informed consent form and receive a unique identification code. They will receive instructions about how to record the variables used in the study and how to complete the GFQ.
Patient inclusion:
Consecutive patients during a working day attending their GP for at least one new reason will be included. It will be considered as a new reason for consultation if it is the first time a particular patient consults the GP for that reason. In those patients with pathologies that present repeated episodes over time (e.g. acute low back pain), when the patient suffers a new episode, it will be considered as a new reason for consultation. Recurrence of cancer in cancer survivors who were considered disease free after cancer treatment will be considered a new diagnosis. Scheduled visits, non-scheduled visits, home visits and telephone contacts will be included. At the end of the consultation, GPs will release an information sheet to each patient with a whole explanation about objectives and procedures of the study. If they agree to participate, they will sign an informed consent form. 
Sample size:
Our sample size estimation was based on the Hjertholm study, [14] which found the prevalence and positive predictive value of cancer suspicion in GPs' consultations to be 6% and 5.4%, respectively. Using an intraclass correlation coefficient correction and a proportion of losses of 10% we will need a sample of 2,966 patients. Majorca and the Zaragoza health sector have a combined population of approximately 970000 inhabitants, 60 health centres and 500 GPs. We expect to recruit 150 GPs. GPs will be encouraged to include almost 20 patients with new reasons for encounter. We estimated 8-10 patients with a new reason for encounter per GP working day; then each GP will need to include patients during 2-3 working days in order to achieve the estimated sample size. During consultations, GPs will check inclusion and exclusion criteria and obtain informed consent. They will record demographic and clinical data and complete the GFQ using a printed version. The actual study will start after a pilot to assess the feasibility.
Data collection:
Follow-up: Two data managers will record the follow-up variables and outcomes. The presence of new diagnoses of cancer or serious disease will be recorded 2 and 6 months after the consultations. New diagnosis will be searched by diagnostic codes and free text notes. The incidence of cancer and serious disease will be assessed by reviewing the hospital and primary care electronic clinical records.
Measurements
Outcomes (Follow-up variables) : At 2 and 6 months after the index visit: -New diagnoses of cancer and serious diseases: o Cancer: all new diagnoses, except non-melanoma skin cancer. o Serious diseases: based on the diseases list used by Hjertholm et al, [14] all new diagnoses will be assessed by two researchers to decide if they are serious or not. Disagreements will be discussed and presented to a third researcher until agreement is reached. -All diagnostic tests performed during the follow-up period. Referrals to specialized care and emergency departments. -Numbers of consultations for any reason during the follow-up period.
Independent variables:
For 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [10] . The validated Spanish and Catalan versions will be used. [12] . The GFQ consists of 11 items. Item 1 (repeated at the end as item 11) assesses whether the patient's case elicited a GF. Items 2-6 are rated using a 5-point Likert scale ranging from completely disagree to completely agree. Item 2 concern the sense of reassurance and items 3-6 concern the sense of alarm. A sense of alarm is considered to be present when the answer to item 1 or 11 indicates a sense of alarm or when the answer chosen at item 1 or 11 is "not applicable" and at least one of the scores of items 3-6 is higher than 3/5. A sense of reassurance is considered to be present when the answer to items 1 or 11 indicates a sense of reassurance or when the answer chosen at items 1 or 11 is "not applicable" and the score for item 2 is higher than 3/5. No type of GF is considered to be present when the answer chosen at item 1 or 11 is "not applicable", none of the scores for items 3-6 is higher than 3/5 and the score for item 2 is lower than 4/5.
Statistical analysis
Objective 1 Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios will be calculated for both sense of alarm and sense of reassurance. For the purpose of this calculation, we will assume that positive values for the sense of reassurance aim to identify the healthy patients, whereas positive values for the sense of alarm aim to identify ill patients. The outcome will be a new diagnosis of cancer, a cancer recurrence or a serious disease during the follow-up period. Information on a new diagnosis of cancer or a cancer recurrence will be given globally and specifically. Confidence intervals will be obtained for each parameter. Bivariate analysis will be used to explore the relationship between the sense of alarm and sense of security and the patient and GP characteristics.
Objective 3. A bivariate analysis, in which each of the main variables (presence of sense of reassurance or sense of alarm) will be compared with the patient and GP characteristics. Chi square test analysis will be carried out in case of categorical variables and Student T test or ANOVAs in case of continuous variables. Multivariate logistic regression analysis will be used to assess the independent relationships between the variables and the presence of GFs. Interactions will be tested. SPSS software will be used for the analysis.
Schedule
All the documents (information sheet, informed consent forms, data collection sheets) have already been designed. Data will be collected during May, June and July 2019. Follow-up variables will be collected during August, September and October 2019 (2- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Ethics
GPs will explain to their patients the study objectives and procedures and request their agreement to collect information from their clinical records. If they agree to participate, patients will sign an informed consent form. The study will be carried out in accordance with the principles of the Helsinki statement and good clinical practice standards.
The study has obtained approval of the Majorcan Primary Care Research Committee and the Balearic Islands Ethical Committee, with reference number IB 3210/16 PI.
Limitations
The sample size necessary to perform a diagnostic validity study of these characteristics is very large. The design we chose aims to have minimal impact on the consultations of the collaborating doctors, in order to facilitate their participation and the inclusion of patients. It is also a very adaptable design, since the number of recruitment days can be increased until the desired sample size is reached, although efforts will be made to include a large number of professionals to ensure sufficient practice variation. Selection bias is controlled by the consecutive inclusion of patients and by the instructions previously given to the collaborating physicians. To minimize the number of missing diagnostic records, the patient files of both primary and hospital care will be thoroughly reviewed. In case of doubt, the seriousness of the diagnoses will be confirmed by peer review. The results of the study may be influenced by the Hawthorne effect a change in the subject's behaviour due to the knowledge that their behaviour is being studied can be a source of bias. [21] Participant GPs may tend to perform more accurately during the diagnosis process of included cases and diagnostic value of GF be overestimated.
Dissemination
This study is part of the corresponding author's PhD project, and its results will be published as part of the thesis, in open access journals, and presented at medical conferences. Where the full study protocol can be accessed 10 30
Sources of funding and other support; role of funders 10 AIM STARD stands for "Standards for Reporting Diagnostic accuracy studies". This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.
EXPLANATION
A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as having a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.
The test whose accuracy is evaluated is called index test. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the reference standard. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.
DEVELOPMENT
This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.
More information can be found on http://www.equator-network.org/reporting-guidelines/stard. 
Introduction
Methods and analysis
Prospective observational study of diagnostic validity. Participation will be offered to GPs from Majorca and Zaragoza (Spain). They will recruit all patients with a new reason for encounter during one or two workdays. GPs will complete the Gut Feelings Questionnaire (GFQ). Variables regarding patient, GP and consultation will be collected. Two and six months after the first visit, incident diagnoses of cancer or other serious diseases, diagnostic tests performed, referrals and new visits will be recorded.
Ethics and dissemination
Strengths and limitations of this study
-This is the first study to use an objective tool (the Gut Feeling Questionnaire) to assess the prevalence and the diagnostic value of GFs for the diagnosis of cancer and other serious diseases. -We will analyse variables that can affect the prevalence and diagnostic value of GFs. -The study will focus on both types of GF: the sense of alarm and the sense of reassurance. -The results of this study may help to estimate the extent to which GPs' gut feelings can contribute to the diagnosis of cancer and serious diseases. -The results of the study might be influenced by the Hawthorne effect. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Establishing a diagnosis of cancer in primary care presents many difficulties. A cancer diagnosis is not a rare event, since a general practitioner (GP) with 2000 registered patients will see 6-8 new cases per year. But a GP will on average diagnose a case of each of the most common cancers (colorectal, prostate, breast, and lung) only once a year, and less frequent cancers might be seen only once or twice during a GP's career. [1] In addition, signs and symptoms of cancer are different for each cancer type, and these signs and symptoms are also very common in other, mostly mild, diseases. Even those considered to be alarming symptoms have low positive predictive values for cancer diagnosis; only eight signs and symptoms (rectal bleeding, iron deficiency anaemia, haematuria, rectal examination showing malignancy, haemoptysis, dysphagia, breast lump and postmenopausal bleeding) have a positive predictive value above 5%.[2]. Since half of cancer patients do not have alarming symptoms [3] , there is a growing interest in finding new elements in the diagnostic process that would lead to an earlier diagnosis in primary care with better survival results.
Uncertainty is an intrinsic component of any clinical encounter in general practice. To cope with it, GPs not only use analytical processes, but sometimes also rely on what they call a gut feeling (GF) or an intuition. [4] Gut feelings have been described as "a useful warning light that goes on suddenly to announce that there is something unusual". [5] It is in the grey area of common symptoms and vague signs, where uncertainty dominates, that GPs might gain the greatest benefit of becoming aware of GFs. When they do so, they have to ask more specific questions, adopt an even more attentive attitude, and observe more accurately to identify the trigger that gave them the sense of alarm. The role of gut feelings in the GP's diagnostic process has been studied in countries such as the Netherlands, Belgium, France and Spain. [6] [7] [8] [9] These studies show two types of GF. The first one is a sense of alarm, described as the feeling that something does not fit for a particular patient, making the GP worried about a possible serious outcome. The second type of GF consists of a sense of reassurance, in which the doctor is sure about the future evolution and management of the patient, even if he/she does not yet know the precise diagnosis. The majority of studies on GFs carried out so far have used qualitative methodology. As a result of the findings, Dutch and Belgian researchers have created and validated the Gut Feelings Questionnaire (GFQ) to objectify their occurrence in clinical encounters. [10] The Dutch GFQ has been translated and linguistically validated into English, French, German, Polish, Spanish, and Catalan. [11, 12] 
Limitations of existing literature
The sense of alarm arises especially when diffuse symptoms are suspected to hide a neoplasm [6, 7, 9] . The role of GFs in the diagnosis of cancer has been little studied so far. In an English study, 55 GPs were interviewed about the role of GFs in the screening and early diagnosis of cancer.
[13] They referred to GFs as a tool, developed through experience, useful to identify patients who need more complementary tests, either to confirm or rule out the possible presence of cancer. Norwegian GPs were asked how they came to think of cancer in a clinical encounter. [4] They mentioned intuition and GFs as one of the ways in which that idea arises. They described GFs as resulting from their medical knowledge, accumulated expertise and knowledge about the patient and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 5 their community. There have also been two Danish studies using a quantitative approach to determine the accuracy with which GPs diagnose cancer. In one of them, 4518 consultations were studied. [14] After each consultation, the GP answered the question whether he had any suspicion of cancer or serious illness. The suspicion of cancer had a positive predictive value (PPV) of 3.1% and a negative predictive value (NPV) of 99.5% six months after the consultation. The other study examined the reasons for referral for further diagnostic workup in a cancer pathway among 1218 patients with nonspecific symptoms and signs. [15] GPs' gut feelings were the second most common reason for referral (22.5% of cases) and a cancer diagnosis was established in 24% of these cases. Dutch GPs reported GFs relating to the diagnosis of cancer in 20 out of 10,000 registered patients a year. These GFs were more likely to arise for patients with weight loss and patients who visited their GP infrequently. The predictive value of GFs for cancer diagnosis was 35%, a value that increased with patients' or GPs' age. [16] We aim to study the diagnostic value of the GFQ for the diagnosis of cancer. Some studies have suggested that this diagnostic validity may be comparable to that of the recognized cancer alarm symptoms.[2,17] If these results were confirmed, a GP's sense of alarm about possible cancer could be regarded as another alarm symptom or "red flag". GFs could be incorporated into the clinical training about the diagnostic process for medical students and residents. In addition, we will also address the sense of reassurance. Just like the GPs reported in previous qualitative literature, we think that it could be a very useful tool for doctors and patients for to avoid unnecessary tests that could result in overmedicalization and overdiagnosis.
Objectives
The aim of the study is to assess the diagnostic value of GPs' sense of alarm and sense of reassurance (in terms of sensitivity, specificity, predictive values and likelihood ratios) for cancer and other serious diseases in clinical consultations. We will also asses the relationships, if any, between the diagnostic value of GFs and patient characteristics (sociodemographic and clinical) and with GP characteristics (gender, experience, personality, type of practice, and knowledge about the patient) will also be assessed. A secondary objective is to establish the prevalence of GFs in GPs' consultations, as well as the possible relationship between the prevalence of GFs and patient and GP characteristics. We aim to estimate the relationship between GFs (sense of alarm and sense of reassurance) and requests for tests and investigations as well as referrals to hospital specialists.
Methods and analysis
This is a prospective observational study using the Spanish and Catalan versions of the GFQ. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 GPs from the regions of Majorca and Zaragoza sector 1 (Spain) will be invited to participate. In Spain every GP has his/her own patient lists. Patients are mainly attended by their GP at their health centre, except during holidays, sick-leave or in out-of-hours visits.
Participants
GP inclusion:
Patient inclusion:
Consecutive patients consulting their GPs for at least one new reason during a working day will be included. A new reason for consultation is defined as the first time a particular patient consults the GP for this reason. For those patients with pathologies that present in repeated episodes over time (e.g. acute low back pain), a new episode will be regarded as a new reason for consultation. Recurrence of cancer in cancer survivors who were considered disease-free after cancer treatment will also be reagarded as a new diagnosis. Scheduled visits, non-scheduled visits, home visits and telephone contacts will be included. At the end of the consultation, GPs will hand over an information sheet to each patient with a full explanation of the objectives and procedures of the study. If they agree to participate, they will sign an informed consent form. 
Sample size:
Our sample size estimation was based on the Hjertholm study, [14] which found the prevalence and positive predictive value of cancer suspicion in GPs' consultations to be 6% and 5.4%, respectively. Using an intraclass correlation coefficient correction and a proportion of losses of 10% we will need a sample of 2,966 patients. The Majorca and Zaragoza health sectors include a combined population of approximately 970000 inhabitants, 60 health centres and 500 GPs. We expect to recruit 150 GPs, who will be encouraged to include at least 20 patients with new reasons for encounter. We estimate that 8-10 patients per GP working day will consult with a new reason for encounter; so each GP will need to include patients during 2-3 working days in order to achieve the intended sample size. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 During consultations, the GPs will check inclusion and exclusion criteria and obtain informed consent. They will record demographic and clinical data and complete the GFQ using a printed version. The actual study will start after a pilot to assess the feasibility.
Data collection:
Follow-up: Two data managers will record the follow-up variables and outcomes. The presence of new diagnoses of cancer or serious disease will be recorded 2 and 6 months after the consultations. New diagnoses will be searched using diagnostic codes and free text notes. The incidence of cancer and serious disease will be assessed by reviewing the hospital and primary care electronic clinical records.
Measurements
Outcomes (Follow-up variables) [14] all new diagnoses will be assessed by two researchers to decide if they are serious or not. Disagreements will be discussed and presented to a third researcher until agreement is reached. -All diagnostic tests performed during the follow-up period. Referrals to specialized care and emergency departments. -Numbers of consultations for any reason during the follow-up period.
Independent variables:
For the GP:  Age, gender, native language, whether the GP is a trainer or not, rural/urban health centre, years of professional experience, years of caring for the same list of patients.  GP's practice style ( [10] . The validated Spanish and Catalan versions will be used. [12] . The GFQ consists of 11 items. Item 1 (repeated at the end as item 11) assesses whether the patient's case elicited a GF. Items 2-6 are rated using a 5-point Likert scale ranging from completely disagree to completely agree. Item 2 concern the sense of reassurance and items 3-6 concern the sense of alarm. A sense of alarm is considered to be present when the answer to item 1 or 11 indicates a sense of alarm or when the answer chosen at item 1 or 11 is "not applicable" and at least one of the scores of items 3-6 is higher than 3/5. A sense of reassurance is considered to be present when the answer to items 1 or 11 indicates a sense of reassurance or when the answer chosen at items 1 or 11 is "not applicable" and the score for item 2 is higher than 3/5. No type of GF is considered to be present when the answer chosen at item 1 or 11 is "not applicable", none of the scores for items 3-6 is higher than 3/5 and the score for item 2 is lower than 4/5.
Statistical analysis
Objective 1 Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios will be calculated for both sense of alarm and sense of reassurance. For the purpose of this calculation, we will assume that positive values for the sense of reassurance aim to identify the healthy patients, whereas positive values for the sense of alarm aim to identify ill patients. The outcome will be a new diagnosis of cancer, a cancer recurrence or a serious disease during the follow-up period. Information on a new diagnoses of cancer or cancer recurrences will be reported globally and specifically. Confidence intervals will be obtained for each parameter. Bivariate analysis will be used to explore the relationship between the sense of alarm and sense of security and the patient and GP characteristics.
Objective 3. A bivariate analysis will be carried out, in which each of the main variables (presence of sense of reassurance or sense of alarm) will be compared with the patient and GP characteristics. The chi square test analysis will be used for categorical variables, and Student T-test or ANOVA for continuous variables. Multivariate logistic regression analysis will be used to assess the independent relationships between the variables and the presence of GFs. Interactions will be tested. SPSS software will be used for the analysis.
Schedule
All the documents (information sheet, informed consent forms, data collection sheets) have already been designed. Data will be collected during May, June and July 2019. Follow-up variables will be collected during August, September and October 2019 (2- 
Ethics
Limitations
The sample size necessary to perform a diagnostic validity study of these characteristics is very large. The design we chose aims to have minimal impact on the consultations of the collaborating doctors, in order to facilitate their participation and the inclusion of patients. It is also a very adaptable design, since the number of recruitment days can be increased until the desired sample size is reached, although efforts will be made to include a large number of doctors to ensure sufficient practice variation. Selection bias is controlled by the consecutive inclusion of patients and by the instructions previously given to the collaborating physicians. To minimize the number of missing diagnostic records, the patient files of both primary and hospital care will be thoroughly reviewed.
In case of doubt, the seriousness of the diagnoses will be confirmed by peer review. We are aware that the Hawthorne effect, that is, a change in a subject's behaviour due to the awareness of being studied can be a source of bias. [21] Participant GPs may thus perform differently than they would normally do, which may affect the estimation of the diagnostic value of GFs.
Dissemination
This study is part of the corresponding author's PhD project, and its results will be published as part of the thesis and in open access journals, and presented at medical conferences. On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)
Where and when potentially eligible participants were identified (setting, location and dates) 6 9
Whether participants formed a consecutive, random or convenience series 6 How indeterminate index test or reference standard results were handled 8 16
How missing data on the index test and reference standard were handled 7 17
Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory 8 18
Intended Where the full study protocol can be accessed 10 30
Sources of funding and other support; role of funders 10 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y STARD 2015 AIM STARD stands for "Standards for Reporting Diagnostic accuracy studies". This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.
EXPLANATION
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" table), several other accuracy statistics can be estimated, such as the positive and negative predictive values of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical precision of the measurements.
If the index test results can take more than two values, categorization of test results as positive or negative requires a test positivity cut-off. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test.
The intended use of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The clinical role of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.
Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.
DEVELOPMENT
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